Risk Factors for Nonischemic St-segment Elevation in Patients With Electrocardiographic Left Ventricular Hypertrophy

Haisen Guo  
Shantou central hospital

Weidai Zhang  
Shantou Central Hospital

Jiawei Zhang  
the First affiliated hospital of Shantou University Medical College

Chumin Ni  
Shantou Central Hospital

Zhixiong Cai  
Shantou Central Hospital

Songming Chen  
the First Affiliated Hospital of Shantou University Medical College

Xiansheng Huang  (✉ hxs0754@163.com)  
Department of Cardiology, the First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, 515000, China.  https://orcid.org/0000-0001-6605-1378

Research article

Keywords: Chest pain, Diagnosis, Echocardiography, Left ventricular hypertrophy, ST-segment elevation

DOI: https://doi.org/10.21203/rs.3.rs-136160/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background** ST-segment elevation (STE) is not a specific change for ST-segment elevation myocardial infarction (STEMI). This may lead to a mistaken diagnosis of STEMI and false-positive cardiac catheterization laboratory activation. We aimed to investigate risk factors for STE secondary to electrocardiographic LVH in order to provide more information for differential diagnosis.

**Methods** A total of 1,590 inpatients with electrocardiographic LVH without confounding factors (such as myocardial infarction) were enrolled in this study. Data on potential risk factors and patient characteristics were collected. Logistic regression analysis and receiver operating characteristic curve (ROC) were used to identify the risk of STE in patients with LVH.

**Results** After reviewing the ECGs, 1590 cases of electrocardiographic LVH were divided into an ST-segment elevation group (STE group, 81 cases) and non-ST segment elevation group (1509 cases). Eighty-seven cases were randomly selected from the non-ST segment elevation group to form a new non-ST segment elevation group (non-STE group, 87 cases) for further analysis. The mean age of the 168 participants (119 men, 70.83%) was 62.33 ± 16.27. Multivariate analysis showed that stroke, infection, and the value of $S_{V1}+R_{V5}$ were significantly associated with STE secondary to LVH. The area under the receiver operating characteristic curve showed that the optimal value of $S_{V1}+R_{V5}$ cut-off for predicting STE was 4.805 (sensitivity: 40.74%; specificity: 80.46%; AUC: 0.634; 95% CI: 0.550–0.719; $P < 0.05$).

**Conclusions** A value of $S_{V1}+R_{V5}$ larger than 4.8 mV, stroke, and infection are independent risk factors for STE in patients with electrocardiographic LVH.

**Background**

ST-segment elevation myocardial infarction (STEMI) is usually caused by unstable plaque rupture of the coronary arteries, resulting in myocardial necrosis in the corresponding perfusion area, and is one of the most common fatal chest pains in the emergency department $^{1-4}$. Rapid diagnosis and shortening of reperfusion therapy time are essential for reducing mortality and improving outcomes in STEMI patients $^{1,5}$. The diagnosis of STEMI is based primarily on symptoms, electrocardiograms (ECG), and myocardial markers $^{1,5}$. ECG is a powerful clinical tool to assist physicians in arriving at the correct diagnosis and determining proper therapy, in particular the reperfusion therapy $^{6}$. The typical ECG changes of myocardial infarction are characterized by ST-segment elevation (STE). However, ECG is an imperfect tool in this setting $^{6}$. STE is not a specific for a change in SETMI. STE can also appear in benign, nonischemic presentations, such as electrocardiographic left ventricular hypertrophy (LVH) $^{7,8}$. Patients with electrocardiographic LVH can develop complex ST-T changes (including STE), which may lead to a mistaken diagnosis of STEMI $^{9-14}$. Previous studies have shown that electrocardiographic LVH is the most significant independent risk factor in leading to a mistaken diagnosis of STEMI and false-positive cardiac catheterization laboratory activation $^{11,12}$. 
Current guidelines fail to provide a fast and effective method to identify STEMI in patients who have combined electrocardiographic LVH with STE\(^1\). Most studies look for ECG characteristics and clinical features of STEMI patients combined with LVH to help identify cases of myocardial infarction\(^6,15-17\). To date, no clinical studies have been conducted to investigate the clinical features of electrocardiographic LVH in patients with STE when myocardial infarction is excluded. The aim of this study was to investigate the risk factors for STE secondary to electrocardiographic LVH in order to provide information that can be used for differential diagnosis.

**Method**

**Study Population** A retrospective analysis was carried out for patients with electrocardiographic LVH at the First Affiliated Hospital of Shantou University Medical College between July 2015 and June 2017. Inclusion criteria included: (1) an ECG that conformed to Sokolow-Lyon criteria: \(R_{V5} + S_{V1} \geq 4.0\) mV (males), \(R_{V5} + S_{V1} \geq 3.5\) mV (females)\(^18\); (2) a patient age older than 18 years. Exclusion criteria included: (1) confounding factors that may affect the ST-segment, such as acute myocardial infarction, old myocardial infarction, conduction block, ectopic rhythm, pacemaker implantation, myocarditis, pericarditis, congenital heart disease, or cardiomyopathy; (2) ECGs where the \(R_{V5} + S_{V1}\) could not be measured, such as ventricular fibrillation, ventricular flutter, continuous pacing rhythm, and cardiac arrest.

Electrocardiographic features were collected by experienced cardiovascular physicians. ST-segment elevation is defined as an STE that appeared in any ECG lead and an elevation amplitude greater than 0.05 mV\(^1\). According to the STE status in the electrocardiogram, participants were divided into an STE group and non-STE group. Eighty-seven patients were randomly selected from the non-STE group by computer to form a new non-STE group for analysis.

**Data collection** Clinical data of patients in the STE group and new non-STE group were collected. We considered the following covariates as potential confounders: gender, age, fever (body temperature greater than 38°C), infection (required antibiotic treatment), acute chest pain, stroke (cerebral hemorrhage, cerebral infarction), biliary system disease (cholecystitis, biliary obstruction), history of hypertension, history of diabetes, history of coronary heart disease, smoking history, heart rate, blood pressure, white blood cells, hemoglobin, platelets, serum potassium ions, serum sodium ions, serum calcium ions, alanine acid transaminase (ALT), serum creatinine, cardiac enzymes (kinase isoenzyme (CK-MB), cardiac troponin I (cTnI)) and \(S_{V1} + R_{V5}\) values. This study was approved by the Ethics Committee of the First Affiliated Hospital of Shantou University Medical College.

**Statistical analysis** Continuous variables are expressed as mean ± SD or medians (interquartile range) as appropriate. Categorical variables are presented as absolute values and proportions. Continuous variables were compared using one-way analysis of variance. Categorical variables were compared using the \(\chi^2\)-test or Fisher’s exact test, as appropriate. Logistic regression analysis was used to estimate odds ratios (OR) for STE and their corresponding 95% confidence intervals (CI). Univariate regression analysis was performed to evaluate the association between clinical variables and STE secondary to LVH.
Variables that were statistically significant in the univariate analysis were entered into a multivariable logistic model. The area under the receiver operating characteristic curve (AUC) was determined to assess the discriminative ability of clinical variables in predicting STE. All statistical analyses were performed using SPSS Statistics version 23.0 (IBM Corporation, Armonk, NY, USA) and HemI 1.0 (Huazhong University of Science and Technology, Hubei, China). An \( \alpha \) level of 0.05 was deemed significant for all analyses.

**Results**

**Baseline characteristics** A total of 67,589 electrocardiograms from the First Affiliated Hospital of Shantou University Medical College between July 2015 and June 2017 were collected. After screening based on our inclusion and exclusion criteria, 21,054 inpatient ECGs were enrolled for further analysis. After reviewing the ECGs, 1590 cases of electrocardiographic LVH, but without confounding factors, were collected and divided into an ST-segment elevation group (STE group, 81 cases) and non-ST segment elevation group (1509 cases). Eighty-seven cases were randomly selected from the non-ST segment elevation group to form a new non-ST segment elevation group (non-STE group, 87 cases) for analysis. The detailed process for participants selection is detailed in Fig. 1.

The clinical characteristics are shown in Table 1. The mean age of the 168 participants (119 men, 70.83%) was 62.33 ± 16.27 years. There were significant differences in ratio of fever, stroke, infection, heart rate, and \( S_{V1}+R_{V5} \) between STE and non-STE groups \( (P<0.05, \text{Table 1}) \). Comparing with the non-STE groups, the ratio of fever, stroke, heart rate and infection were higher in the STE group. Other factors such as gender ratio, age, biliary tract disease, acute chest pain, history of hypertension, history of diabetes, history of coronary heart disease, and smoking history did not have significant difference between the STE group and non-STE group.
| Characteristic                        | Overall (n = 168) | STE Group (n = 81) | Non-STE Group (n = 87) | P     |
|---------------------------------------|-------------------|-------------------|------------------------|-------|
| Sex, male (%)                         | 119 (70.83)       | 55 (67.90)        | 64 (73.56)             | 0.420 |
| Age, years                            | 62.33 ± 16.27     | 61.99 ± 17.16     | 62.64 ± 15.49          | 0.795 |
| Fever, n (%)                          | 22 (13.10)        | 15 (18.52)        | 7 (8.05)               | 0.044 |
| Acute chest pain, n (%)               | 12 (7.14)         | 8 (9.88)          | 4 (4.60)               | 0.304 |
| Stroke, n (%)                         | 32 (19.05)        | 22 (27.16)        | 10 (11.49)             | 0.011 |
| Biliary system diseases, n (%)        | 3 (1.79)          | 3 (3.70)          | 0                      | 0.110 |
| Infection, n (%)                      | 60 (35.71)        | 37 (45.68)        | 23 (26.44)             | 0.009 |
| Hypertension, n (%)                   | 118 (70.24)       | 53 (65.43)        | 65 (74.71)             | 0.189 |
| Diabetes, n (%)                       | 37 (22.02)        | 16 (19.75)        | 19 (21.84)             | 0.739 |
| Coronary heart disease, n (%)         | 12 (7.14)         | 6 (7.41)          | 6 (6.90)               | 0.898 |
| Smoking, n (%)                        | 48 (28.57)        | 21 (25.93)        | 27 (31.03)             | 0.464 |
| Heart rate (bpm)                      | 84.95 ± 17.33     | 87.75 ± 19.88     | 82.34 ± 14.18          | 0.046 |
| SBP, mmHg                             | 150.40 ± 32.38    | 151.15 ± 34.09    | 149.70 ± 30.90         | 0.773 |
| DBP, mmHg                             | 86.48 ± 20.42     | 85.77 ± 23.40     | 87.15 ± 17.32          | 0.665 |
| WBC, 10^9/L                           | 9.95 ± 6.87       | 9.47 ± 4.57       | 10.41 ± 8.47           | 0.376 |
| Hb, g/L                               | 115.35 ± 31.83    | 119.46 ± 34.60    | 111.48 ± 28.65         | 0.106 |
| PLT, 10^9/l                           | 222.31 ± 90.31    | 212.49 ± 88.85    | 231.66 ± 91.22         | 0.172 |
| Serum K⁺, mmol/L                      | 3.87 ± 0.63       | 3.83 ± 0.62       | 3.90 ± 0.63            | 0.450 |
| Serum Na⁺, mmol/L                     | 137.78 ± 5.00     | 137.33 ± 4.59     | 138.21 ± 5.27          | 0.254 |
| Serum Ca⁺, mmol/L                     | 2.16 ± 0.20       | 2.16 ± 0.24       | 2.15 ± 0.17            | 0.744 |
| Alanine acid transaminase, U/L        | 17.00 (11.75-27.00) | 18.50 (13.00-29.75) | 16.50 (11.00-26.25)    | 0.735 |

Data given as mean ± SD, median (IQR), or n (%). *P*-value of < 0.05 was considered significant.

Ck-MB, creatine kinase isoenzyme-MB; DBP, diastolic blood pressure; SBP, systolic blood pressure; TNI, Troponin I; WBC, white blood cells; Hb, hemoglobin; PLT, platelets.
| Characteristic                  | Overall (n = 168) | STE Group (n = 81) | Non-STE Group (n = 87) | P      |
|--------------------------------|------------------|-------------------|------------------------|--------|
| Serum creatinine, µmol/L       | 114.00 (87.00-211.00) | 116.00 (85.00-254.00) | 111.50 (87.00-192.50) | 0.805  |
| CK-MB, ng/mL                   | 1.80 (1.80–2.11)  | 1.80 (1.80–2.13)  | 1.80 (1.80–2.11)       | 0.842  |
| cTnI, ng/mL                    | 0.1 (0.1–0.21)    | 0.1 (0.1–0.25)    | 0.1 (0.1–0.18)         | 0.564  |
| Positive cTnI, n (%)           | 8 (4.76)          | 5 (6.17)          | 3 (3.45)               | 0.484  |
| $S_{V1}+R_{V5}$(mV)            | 4.59 ± 1.00       | 4.85 ± 1.17       | 4.35 ± 0.72            | 0.001  |

Data given as mean ± SD, median (IQR), or n (%). *P*-value of < 0.05 was considered significant.

Ck-MB, creatine kinase isoenzyme-MB; DBP, diastolic blood pressure; SBP, systolic blood pressure; TNI, Troponin I; WBC, white blood cells; Hb, hemoglobin; PLT, platelets.

**Association between clinical variables and STE** Univariate regression analysis showed that the ratio of fever, stroke, infectious disease, heart rate, and value of $S_{V1}+R_{V5}$ were significantly associated with STE (Table 2).

**Table 2**
Factors associated with STE in patients with LVH (univariable analysis)

| Variables            | Univariate |          |
|----------------------|------------|----------|
|                      | **OR (95% CI)** | **P**   |
| Fever                | 2.60 (1.05, 6.75) | < 0.05   |
| Heart rate           | 1.02 (1.01, 1.04) | < 0.05   |
| $S_{V1}+R_{V5}$      | 1.80 (1.24, 2.60) | < 0.01   |
| Infectious disease   | 2.34 (1.22, 4.47) | < 0.05   |
| Stroke               | 2.83 (1.25, 6.44) | < 0.05   |

CI, confidence interval; a *P*-value of < 0.05 was considered significant. STE, ST-segment elevation; LVH, left ventricular hypertrophy; OR, Odds ratio.

**Multivariate logistic regression analysis** Variables that were statistically significant in univariate analysis were entered into a multivariable logistic model. Stroke (OR, 3.11; 95% CI, 1.31–7.39; *p* = 0.01), infection (OR, 2.08; 95% CI, 1.05–4.12; *p* = 0.04), and value of $S_{V1}+R_{V5}$ (OR, 1.88; 95% CI, 1.29–2.75; *p* < 0.01) remained independently associated with the outcome in our multivariable model (Fig. 2).
Optimal $S_{V1} + R_{V5}$ index cut-off for predicting STE  

The area under the receiver operating characteristic curve (ROC) showed that the optimal $S_{V1} + R_{V5}$ cut-off value for predicting STE in patients with LVH, as determined using the Youden index, was 4.805 (sensitivity: 40.74%; specificity: 80.46%; AUC: 0.634; 95% CI: 0.550–0.719; $P < 0.05$) (Fig. 3).

Discussion

LVH alters the measurement of cardiac repolarization. Characteristic ECG changes associated with LVH including STE, prominent septal Q waves, T-wave inversion, and ST-segment depression, which may lead to misdiagnosis of acute myocardial infarction. The presence of LVH, when associated with STE, has been demonstrated as a risk factor for false-positive ST-segment elevation myocardial infarction diagnoses, commonly leading to unnecessary reperfusion therapy. Chest pain centers have been built in many countries. Chest pain centers have been shown to shorten the reperfusion therapy time, which is associated with better outcomes for myocardial infarction patients. However, in order to shorten the reperfusion time, physicians at chest pain centers often do not have enough time for careful differential diagnosis. Previous studies have shown that in the early stages of chest pain center construction, the incidence of false activation of cardiac catheterization laboratory increased, and the occurrence of false activation events was closely related to electrocardiographic LVH. More seriously, previous publications have shown that LVH with STE is an independent risk factor for misdiagnosing STEMI in patients with aortic dissection. Aortic dissection is a catastrophic disease with rapid onset, rapid progression, high mortality, and poor natural prognosis. Patients with aortic dissection who are misdiagnosed as STEMI will lead to serious consequences. Therefore, physicians should be keenly aware of the possibility of LVH confounding the ability to recognize true STEMI. For patients with STE, physicians need to quickly identify patients with true STEMI for reperfusion treatment, while minimizing misdiagnosis of nonischemic diseases as STEMI to avoid iatrogenic damage. Thus, it is necessary to reduce misdiagnosis by finding a method that can be used to identify STE secondary to LVH and ischemic STE.

However, STEMI guidelines do not define STE diagnostic thresholds for LVH patients. The 2017 ESC Guidelines for the management of acute myocardial infarction indicate that STE is considered suggestive of ongoing coronary artery acute occlusion in the following cases: at least two contiguous leads with $STE > 0.1$ mV in all leads other than leads $V_2-V_3$, where the following cutoff points apply: $STE > 0.2$ mV in men $\geq 40$ years, $STE \geq 0.25$ mV in men $< 40$ years, or $STE \geq 0.15$ mV in women [in the absence of LVH or left bundle branch block (LBBB)]. The 2013 ACCF/AHA guidelines for the management of STE myocardial infarction define diagnostic STE, in the absence of LVH or left LBBB, as new STE at least 1 mm (0.1 mV) in two or more anatomically contiguous leads (with allowance of up to 1.5 mm (0.15 mV) in leads $V_2-V_3$ for women and 2 mm (0.2 mV) in the same leads for men). Interestingly, these guidelines define diagnostic thresholds in the absence of LVH, but the guidelines do not clarify how to
diagnose STEMI in the case of LVH, which might result in many unnecessary, potentially dangerous coronary angiographies.

Based on the deficiencies of current clinical guidelines, we need to find more methods to help clinicians make a differential diagnosis. There have been many studies looking for ECG characteristics and clinical features of STEMI patients with LVH to help identify cases of myocardial infarction. For example, a study by Armstrong et al. suggested using a ratio of ST-segment to R-S-wave magnitude ≥ 25% as a diagnostic criteria for STEMI to improve specificity of diagnosis in patients with anterior territory STE. However, using these additional ECG diagnostic criteria and clinical features to identify STEMI may reduce the sensitivity of the ECG for STEMI diagnosis. To date, no clinical studies have been performed to identify independent predictors of STE in nonischemic patients with LVH. Therefore, we tried to investigate the risk factors for STE in patients with LVH but without STEMI in order to provide more information for differential diagnosis.

**Risk factors for STE** After researching the literature, we collected and analyzed common potential risk factors that may affect the ST segment. According to multivariate logistic regression analysis, a value of $S_{V1}+R_{V5}$ larger than 4.8 mV is an independent risk factor for STE in patients with electrocardiographic LVH. $S_{V1}+R_{V5}$ is the main indicator of the Sokolow- Lyon standard in diagnosing LVH, which reflects the projection of the largest vector of the left ventricular depolarization on the horizontal plane. Our study further finds that the value of $S_{V1}+R_{V5}$ could not only be used to diagnose electrocardiographic LVH, but also that the magnitude of $S_{V1}+R_{V5}$ is positively correlated with the risk of nonischemic STE. Therefore, LVH patients combined with STE and an elevated $S_{V1}+R_{V5}$ (larger than 4.8 mV) should be highly suspect for the possibility of secondary nonischemic STE. Conversely, if STE occurs when $S_{V1}+R_{V5}$ is not significantly elevated (less than 4.8 mV), then STEMI might be considered to avoid misdiagnosis and delaying primary angioplasty. To determine how the $S_{V1}+R_{V5}$ performs to differentiate between ischemic STE and nonischemic STE secondary to LVH, a threshold of 4.8 mV was chosen by optimizing receiver operating characteristic (ROC) curves. For a patient with an $S_{V1}+R_{V5}$ larger than 4.8 mV, physicians should be keenly aware of the possibility of nonischemic STE secondary to LVH. Otherwise, STEMI should be considered. The specificity is high (0.8) but the sensitivity is low (0.4) on the ROC curve. Given that missed diagnosis of STEMI could lead to serious consequences, high specificity is needed to minimize the possibility of missed diagnosis. Considering that the magnitude of $S_{V1}+R_{V5}$ is an additional auxiliary differential diagnosis method, lower sensitivity is acceptable. Therefore, a value of $S_{V1}+R_{V5}$ greater than 4.8 mV could be used for clinical differential diagnosis and is worth further research.

We also found that stroke is related with the incidence of STE in patients with LVH. Patients with stroke are more likely to have STE, and the incidence of STE is 2.11-fold higher than that without stroke. The mechanism is not clear. We believe this might be related to brain-heart interaction, a group of heart disease secondary to central nervous system disorders, such as stroke. Previous publications have reported that ECG abnormalities in stroke occur in 70%-80% of cases, and are mainly represented as ST-T
abnormalities (including STE) \(^{27-30}\). In the current study, we found that superimposed stroke based on electrocardiographic LVH results in a significant increase in the incidence of STE.

Previous publications indicate that infection has important effects on the cardiovascular system. That pneumonia is a risk factor for acute cardiac complications has been documented thoroughly in several large cohorts \(^{31,32}\). Therefore, we included infection as a potential risk factor in the logistic regression analysis. According to the results of the multiple logistic regression analysis, patients combined with infection and electrocardiographic LVH are more prone to STE, and the incidence of STE is increased by 108% compared with non-infected patients. Several mechanisms, related to the systemic response to infection, can account for the ST-T change. Acute inflammation can influence cardiac metabolic supply-to-demand ratio, depress myocardial function and increase left ventricular afterload \(^{32-34}\).

Given the high incidence of LVH, our findings have important implications. Clinicians need to realize the importance of secondary STE in patients with LVH and exercise appropriate clinical alertness to avoid misdiagnosing non-ischemic STE as ischemic STE. An adequate estimation of the risk of STE secondary to electrocardiographic LVH will require new strategies that adequately weigh clinical factors associated with non-ischemic STE in our study. We found that a value of \(S_{V1}+R_{V5}\) larger than 4.8 mV, stroke, and infectious disease are independent risk factors for STE in patients with LVH. Physicians should be keenly aware of the possibility of nonischemic STE secondly to LVH in patients with an \(S_{V1}+R_{V5}\) larger than 4.8 mV, or combined with infection or stroke to avoid false-positive cardiac catheterization laboratory activation. It should be emphasized that since we have eliminated other factors that may cause ST segment elevation, such as myocardial infarction, the myocardial enzymes in most of the cases we included are normal. Therefore, applying the conclusion of this research to cases with normal myocardial enzymes might have higher specificity.

**Limitations** First, we analyzed the clinical features of patients with STE caused by LVH to help differential diagnosis. However, we did not explore the clinical features of STEMI with LVH. However, risk factors, such as hypertension, diabetes, hyperlipidemia, and smoking history, have been identified as risk factors for STEMI \(^1\). These risk factors, which have been widely used to identify ischemic STE and STE secondary to LVH in clinical practice, may be important clinical features of STEMI in patients with LVH. Second, we did not collect cardiac ultrasound or magnetic resonance (MR) results from cases of electrocardiographic LVH to verify true LVH on structure \(^{35}\). However, previous studies have found that electrocardiographic LVH itself, not depending on structural hypertrophy, is a risk factor for misdiagnosis of STEMI \(^{35}\). Third, there are currently several ECG criteria available for the diagnosis of LVH, including the Sokolow-Lyon standard, Cornell standard, and Gubner-Ungerleider standard. This study only used the Sokolow-Lyon standard to diagnose ECG LVH. However, the Sokolow-Lyon criterion has a higher diagnostic specificity, which is recommended by the guidelines for hypertension \(^{30,36}\). Fourth, the potential influencing factors we included may not be comprehensive, and there may be other potential influencing factors for ST segment elevation that have not been included and analyzed. However, the factors we analyzed cover common clinical indicators and factors already mentioned in the literature.
More importantly, the factors we include in the analysis are easy to obtain, being routine indicators of clinical laboratory tests. Therefore, the potential influencing factors we discussed could be applied to different grades of hospitals, enabling our conclusions to have broader application.

**Conclusion**

Physicians should be keenly aware of the possibility of nonischemic STE secondary to electrocardiographic LVH. An $S_{V1}+R_{V5}$ value larger than 4.8 mV, stroke, and infection are independent risk factors for STE in patients with electrocardiographic LVH.

**Declarations**

**Ethics approval and consent to participate**

The study was approved by the ethics committee of the First Affiliated Hospital of Shantou University Medical College. The need for consent was waived because of the retrospective data. Dr. Xiansheng Huang granted administrative permission to access the raw data.

**Consent to publish**

Not applicable.

**Availability of data and materials**

Raw data supporting the obtained results are available at the corresponding author.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This study was funded by Medical Scientific Research Foundation of Guangdong Province of China (A2019219), and Strategic Fund for Science and Technology Innovation in Guangdong Province (Vertical Collaborative Management Direction) (2018-157-42), and Medical and Health Technology Plan Project of Shantou City (20190927245-4).

**Authors’ contributions**

HG, WZ, XH and JZ contributed to the conception and design, analysis and interpretation of data, drafting of the manuscript. CN, ZC and SC contributed to the collection, analysis, and interpretation of the data. XH contributed to the conception and design and revised it critically for important intellectual content. All authors read and approved the final manuscript.
Acknowledgements

Not applicable.

References

1. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European heart journal. 2018;39(2):119-177.

2. Stepinska J, Lettino M, Ahrens I, et al. Diagnosis and risk stratification of chest pain patients in the emergency department: focus on acute coronary syndromes. A position paper of the Acute Cardiovascular Care Association. European heart journal Acute cardiovascular care. 2020;9(1):76-89.

3. Fan F, Li Y, Zhang Y, et al. Chest Pain Center Accreditation Is Associated With Improved In-Hospital Outcomes of Acute Myocardial Infarction Patients in China: Findings From the CCC-ACS Project. Journal of the American Heart Association. 2019;8(21):e013384.

4. Hasin YJ, Hasin T. Who should manage patients with chest pain in the emergency room? European heart journal. 2015;36(26):1634-1635.

5. Morrow DA. The Fourth Universal Definition of Myocardial Infarction and the Emerging Importance of Myocardial Injury. Circulation. 2020;141(3):172-175.

6. Nable JV, Lawner BJ. Chameleons: Electrocardiogram Imitators of ST-Segment Elevation Myocardial Infarction. Emergency medicine clinics of North America. 2015;33(3):529-537.

7. Jayroe JB, Spodick DH, Nikus K, et al. Differentiating ST elevation myocardial infarction and nonischemic causes of ST elevation by analyzing the presenting electrocardiogram. The American journal of cardiology. 2009;103(3):301-306.

8. Tran V, Huang HD, Diez JG, et al. Differentiating ST-elevation myocardial infarction from nonischemic ST-elevation in patients with chest pain. The American journal of cardiology. 2011;108(8):1096-1101.

9. Pope JH, Ruthazer R, Kontos MC, Beshansky JR, Griffith JL, Selker HP. The impact of electrocardiographic left ventricular hypertrophy and bundle branch block on the triage and outcome of ED patients with a suspected acute coronary syndrome: a multicenter study. The American journal of emergency medicine. 2004;22(3):156-163.

10. Larson DM, Menssen KM, Sharkey SW, et al. "False-positive" cardiac catheterization laboratory activation among patients with suspected ST-segment elevation myocardial infarction. Jama. 2007;298(23):2754-2760.

11. McCabe JM, Armstrong EJ, Kulkarni A, et al. Prevalence and factors associated with false-positive ST-segment elevation myocardial infarction diagnoses at primary percutaneous coronary intervention-capable centers: a report from the Activate-SF registry. Archives of internal medicine. 2012;172(11):864-871.
12. Shamim S, McCrary J, Wayne L, Gratton M, Bogart DB. Electrocardiographic findings resulting in inappropriate cardiac catheterization laboratory activation for ST-segment elevation myocardial infarction. *Cardiovascular diagnosis and therapy*. 2014;4(3):215-223.

13. Rokos IC, French WJ, Mattu A, et al. Appropriate cardiac cath lab activation: optimizing electrocardiogram interpretation and clinical decision-making for acute ST-elevation myocardial infarction. *American heart journal*. 2010;160(6):995-1003, 1003.e1001-1008.

14. Garvey JL, Monk L, Granger CB, et al. Rates of cardiac catheterization cancelation for ST-segment elevation myocardial infarction after activation by emergency medical services or emergency physicians: results from the North Carolina Catheterization Laboratory Activation Registry. *Circulation*. 2012;125(2):308-313.

15. Rude RE, Poole WK, Muller JE, et al. Electrocardiographic and clinical criteria for recognition of acute myocardial infarction based on analysis of 3,697 patients. *The American journal of cardiology*. 1983;52(8):936-942.

16. Menown IB, Mackenzie G, Adgey AA. Optimizing the initial 12-lead electrocardiographic diagnosis of acute myocardial infarction. *European heart journal*. 2000;21(4):275-283.

17. Armstrong EJ, Kulkami AR, Bhave PD, et al. Electrocardiographic criteria for ST-elevation myocardial infarction in patients with left ventricular hypertrophy. *The American journal of cardiology*. 2012;110(7):977-983.

18. Devereux RB, Casale PN, Eisenberg RR, Miller DH, Kligfield P. Electrocardiographic detection of left ventricular hypertrophy using echocardiographic determination of left ventricular mass as the reference standard. Comparison of standard criteria, computer diagnosis and physician interpretation. *Journal of the American College of Cardiology*. 1984;3(1):82-87.

19. Kosuge M, Uchida K, Imoto K, et al. Frequency and implication of ST-T abnormalities on hospital admission electrocardiograms in patients with type A acute aortic dissection. *The American journal of cardiology*. 2013;112(3):424-429.

20. Zhu QY, Tai S, Tang L, et al. STEMI could be the primary presentation of acute aortic dissection. *The American journal of emergency medicine*. 2017;35(11):1713-1717.

21. Hansson EC, Dellborg M, Lepore V, Jeppsson A. Prevalence, indications and appropriateness of antiplatelet therapy in patients operated for acute aortic dissection: associations with bleeding complications and mortality. *Heart (British Cardiac Society)*. 2013;99(2):116-121.

22. Blankenship JC, Almquist AK. Cardiovascular complications of thrombolytic therapy in patients with a mistaken diagnosis of acute myocardial infarction. *Journal of the American College of Cardiology*. 1989;14(6):1579-1582.

23. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*. 2013;61(4):e78-e140.
24. Li W, Li L, Li W, et al. Spleen associated immune-response mediates brain-heart interaction after intracerebral hemorrhage. *Experimental neurology.* 2020;327:113209.

25. Desai R, Singh S, Patel U, et al. Frequency of takotsubo cardiomyopathy in epilepsy-related hospitalizations among adults and its impact on in-hospital outcomes: A national standpoint. *International journal of cardiology.* 2020;299:67-70.

26. Chen H, Zhang Y, Su Y. [Clinical characteristics and prognosis of brain-heart interaction in patients with acute severe stroke]. *Zhonghua wei zhong bing ji jiu yi xue.* 2019;31(8):953-957.

27. Purushothaman S, Salmani D, Prarthana KG, Bandelkar SM, Varghese S. Study of ECG changes and its relation to mortality in cases of cerebrovascular accidents. *Journal of natural science, biology, and medicine.* 2014;5(2):434-436.

28. Adeoye AM, Ogah OS, Ovbiagele B, et al. Prevalence and Prognostic Features of ECG Abnormalities in Acute Stroke: Findings From the SIREN Study Among Africans. *Global heart.* 2017;12(2):99-105.

29. Adeoye AM, Ovbiagele B, Akinyemi JO, et al. Echocardiographic Abnormalities and Determinants of 1-Month Outcome of Stroke Among West Africans in the SIREN Study. *Journal of the American Heart Association.* 2019;8(11):e010814.

30. Bahls M, Könemann S, Markus MRP, et al. Brain-derived neurotrophic factor is related with adverse cardiac remodeling and high NTproBNP. *Sci Rep.* 2019;9(1):15421-15421.

31. Corrales-Medina VF, Musher DM, Shachkina S, Chirinos JA. Acute pneumonia and the cardiovascular system. *Lancet (London, England).* 2013;381(9865):496-505.

32. Corrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L, Fine MJ. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. *Circulation.* 2012;125(6):773-781.

33. Maeder M, Fehr T, Rickli H, Ammann P. Sepsis-associated myocardial dysfunction: diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. *Chest.* 2006;129(5):1349-1366.

34. Geri G, Vignon P, Aubry A, et al. Cardiovascular clusters in septic shock combining clinical and echocardiographic parameters: a post hoc analysis. *Intensive care medicine.* 2019;45(5):657-667.

35. Reichek N, Devereux RB. Left ventricular hypertrophy: relationship of anatomic, echocardiographic and electrocardiographic findings. *Circulation.* 1981;63(6):1391-1398.

36. Tanabe A, Asayama K, Hanazawa T, et al. Left ventricular hypertrophy by electrocardiogram as a predictor of success in home blood pressure control: HOMED-BP study. *Hypertens Res.* 2017;40(5):504-510.

**Figures**
Figure 1

The complete procedure of the participants selection and exclusion. 1 Confounders including acute myocardial infarction, old myocardial infarction, conduction block, ectopic rhythm, pacemaker implantation, myocarditis, pericarditis, congenital heart disease, or cardiomyopathy. ECG= Electrocardiograph; LVH= left ventricular hypertrophy; STE= ST-segment elevation.
| Variable   | OR (95% CI) |
|------------|-------------|
| Stroke     | 3.11 (1.31, 7.39) |
| Infection  | 2.08 (1.05, 4.12) |
| SV1+RV5    | 1.88 (1.29, 2.75) |

**Figure 2**

Multivariate logistic regressions analysis for STE secondary to LVH. LVH = left ventricular hypertrophy; STE = ST-segment elevation.
Figure 3

Receiver operator characteristic (ROC) curve for SV1+RV5 predicting STE in patients with LVH LVH= left ventricular hypertrophy; STE= ST-segment elevation.